Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 231

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 231
---
 22, 2024. The Board of Directors has determined that Dr. Turton, Dr. Parker and Ms. Merchant are
independent under Rule 10A-3 of the Exchange Act and that Dr. Turton qualifies as an “audit committee financial expert” as
defined under in Item 16A of Form 20-F.

| 114 |

The Audit Committee of the
Board of Directors assists the Board of Directors in discharging its responsibilities with regard to financial reporting, external and
internal audits and controls, including reviewing and monitoring the integrity of the Company’s annual and interim financial statements,
advising on the appointment of external auditors, reviewing and monitoring the extent of the non-audit work undertaken by external auditors,
overseeing our relationship with our external auditors, reviewing the effectiveness of the external audit process and reviewing the effectiveness
of our internal control review function. The ultimate responsibility for reviewing and approving the annual report and accounts and the
half-yearly reports remains with the Board of Directors.

In addition, the Audit Committee
is responsible, within agreed terms of reference, for ensuring compliance with the rules and regulations promulgated by the SEC and the
rules of NASDAQ, and disclosure of information.

The Audit Committee meets
not less than twice a year and otherwise as required.

Nomination Committee

The Nomination Committee is
chaired by Dr. Parker and is currently comprised of Dr. Parker, Dr. de Vries and Dr. Turton. The Nomination Committee assists the Board
of Directors in discharging its responsibilities relating to the composition and make-up of the Board of Directors and any committees
of the Board of Directors. It is responsible for periodically reviewing the Board of Director’s structure and identifying potential
candidates to be appointed as directors or committee members as the need may arise. The Nomination Committee is responsible for evaluating
the balance of skills, knowledge and experience and the size, structure and composition of the Board of Directors and committees of the
Board of Directors, retirements and appointments of additional and replacement directors and committee members and will make appropriate
recommendations to the Board of Directors on such matters.

The Nomination Committee meets not less than once
a year and otherwise as required.

Remuneration Committee

The Remuneration Committee
consists of three members: Dr. de Vries (Chairman), Dr. Turton and Ms. Merchant. During 2023, Dr. Parker served on the Remuneration Committee
until the appointment of Ms. Merchant